Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ramy Ramadan
Ramy Ramadan
Associate
Dubai +971 4 247 2115 rramadan@cov.com Download V-card

Ramy Ramadan is a member of the firm’s corporate group. He relocated from the Washington, DC office to the Dubai office in May 2018. His practice focuses on mergers and acquisitions and project development and finance transactions. Mr. Ramadan also advises clients on general corporate matters, securities offerings, and technology and IP transactions.

Mergers and Acquisitions

  • Bacardi in its $5.1 billion acquisition of Patrón Spirits International AG and its PATRÓN® brand, the world’s top-selling ultra-premium tequila, from John Paul DeJoria, a founder of Patrón. 
  • UCB S.A. in its $1.53 billion sale of its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc., to Lannett Company.
  • Egyptian investment bank Beltone Financial Holding in its acquisition of 60% of NY-based Auerbach Grayson & Company.
  • A consortium in its bid to acquire state-owned grain mills in Saudi Arabia.
  • A global beverage company in connection with its partnership with a Fortune 100 company in the Middle East.        
  • A major Middle Eastern energy company in cross-border negotiations for the purchase of security equipment and services.
  • A global dredging company in connection with its contract for the deepening and widening of the Suez Canal.
  • AstraZeneca in:
    • the $575 million acquisition of Takeda’s respiratory business; and
    • the sale of its U.S. and Canada rights to its Zoladex® product to TerSera Therapeutics for up to $350 million.
  • Dutch private equity fund Gilde Equity Management Benelux B.V. in its $41 million acquisition of Onguard Industries from Ansell Limited.    
  • India-based Famy Care Limited in its $750 million sale of its women's health business to Mylan Laboratories Limited.
  • The Collins Family Trust in its $260 million acquisition of Inter National Bank from Grupo Financiero Banorte.
  • Fortune 500 company in its complex joint venture with a major beverage company to develop an in-home system.
  • Eisai Inc. in:
    • the sale of its Research Triangle Park manufacturing campus to Biogen Inc.; and
    • the sale of its subsidiary, AkaRx, Inc., to PBM Capital Group, LLC.

Project Development and Finance

  •  Adenium Energy Capital in the development and financing of a 15 megawatt captive solar power project in Jordan, that will provide electricity to a cement factory owned by LafargeHolcim.
  • A consortium in its bid to develop a wastewater treatment plant in Dammam West, Saudi Arabia.

Capital Markets

  • The underwriters in the $38.1 million initial public offering of common stock of National Commerce Corporation.
  • The underwriters in the $44.6 million initial public offering of common stock of CapStar Financial Holdings, Inc.
  • HealthSouth Corporation in its $300 million offering of 5.125% senior notes due 2023.

Pro Bono

  • An international non-profit organization in a development project in Africa.
  • A global non-governmental organization in connection with legal reform issues in the Middle East.

Previous Experience

  • U.S. Securities and Exchange Commission, Division of Corporation Finance, Law Clerk
  • U.S. Patent and Trademark Office, Patent Examiner
  • U.S. Securities and Exchange Commission, Division of Enforcement, Law Clerk